Search Results
Sep 03, 2026, 08:30 ET Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
N.J., Sept. 3, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman
More news about: Citius Pharmaceuticals, Inc.
Aug 14, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
(Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.
More news about: Citius Oncology, Inc.
Aug 14, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results
More news about: Citius Pharmaceuticals, Inc.
Aug 12, 2026, 08:00 ET Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
(Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10,
More news about: Citius Oncology, Inc.
Aug 05, 2026, 09:17 ET Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued
More news about: Citius Oncology, Inc.
Jul 21, 2026, 09:17 ET Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the commercial launch of LYMPHIR® (denileukin diftitox-cxdl), highlighting continued progress across market
More news about: Citius Oncology, Inc.
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today highlighted Phase 1 clinical data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR
More news about: Citius Oncology, Inc.
May 26, 2026, 08:00 ET Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination
More news about: Citius Oncology, Inc.
May 15, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
N.J., May 15, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and
More news about: Citius Pharmaceuticals, Inc.
May 15, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal second quarter ended March 31, 2026, and provided a business update.
More news about: Citius Oncology, Inc.
Apr 29, 2026, 08:00 ET Citius Oncology Ships First International Order of LYMPHIR™ to Europe
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an
More news about: Citius Oncology, Inc.
Apr 24, 2026, 16:30 ET Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products,
More news about: Citius Pharmaceuticals, Inc.
Apr 24, 2026, 08:00 ET Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products,
More news about: Citius Pharmaceuticals, Inc.
Apr 01, 2026, 07:05 ET Central Texas and Colorado River Railway Sparks Investment in San Saba Region
more efficiently over longer distances."About CTXR RailroadCentral Texas Railroad (CTXR) is a regional rail operator serving industrial, commercial, and logistics customers across Central Texas. An affiliate of OmniTRAX, CTXR provides the modern infrastructure and safe, reliable
More news about: OmniTRAX, Inc.
Mar 31, 2026, 09:11 ET Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl) for the treatment of cutaneous T-cell lymphoma (CTCL),
More news about: Citius Oncology, Inc.
Mar 24, 2026, 08:00 ET Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that members of its commercial and medical affairs teams will attend the USCLC Annual Workshop 2026. The meeting, titled "Frontiers
More news about: Citius Oncology, Inc.
Mar 10, 2026, 08:47 ET Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators.
More news about: Citius Oncology, Inc.
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
(Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl)
More news about: Citius Oncology, Inc.
Feb 24, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the Company
More news about: Citius Pharmaceuticals, Inc.
Feb 13, 2026, 08:00 ET Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update.
More news about: Citius Oncology, Inc.
Feb 13, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and
More news about: Citius Pharmaceuticals, Inc.
Feb 11, 2026, 08:00 ET Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Uniphar ("Uniphar"), a leading international healthcare services
More news about: Citius Oncology, Inc.
Dec 23, 2025, 16:30 ET Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update.
More news about: Citius Oncology, Inc.
Dec 23, 2025, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and
More news about: Citius Pharmaceuticals, Inc.
Dec 10, 2025, 16:30 ET Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, priced at-the-market
More news about: Citius Oncology, Inc.